Skip to main content
. 2015 Oct 14;8(1):87–98. doi: 10.1080/19420862.2015.1106658

Figure 2.

Figure 2.

ABD modified IgAHer2 antibodies bind to albumin and simultaneously bind Her2 and FcαRI. (A) Solid phase binding of unmodified IgA Abs and HCABD and LCABD modified IgA Abs (100 ng/mL) to albumin derived from different species (HSA: 40 ng/mL; mouse, monkey and rat serum: 100,000x diluted) measured by ELISA. (B) Antibody-albumin complex formation in solution was determined by pre-incubating unmodified and HCABD and LCABD modified IgA Abs (130 nM) in the absence or presence of human albumin (130 nM and 260 nM) and subsequent analyses by HP-SEC. Retention time of Abs in the absence of albumin is indicated by a dotted line. (C) Conjugate formation between Her2 (SKBR3) and FcαRI (Ba/F3-FcαRI-eYFP) expressing cells upon simultaneous binding to Abs (20 μg/mL) pre-incubated without (black bar) and with (gray bar) 1 mg/mL HSA (mean ± SEM).